# A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

> **NCT03729245** · PHASE3 · TERMINATED · sponsor: **Nektar Therapeutics** · enrollment: 623 (actual)

## Conditions studied

- Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** bempegaldesleukin
- **DRUG:** sunitinib
- **BIOLOGICAL:** nivolumab
- **DRUG:** cabozantinib

## Key facts

- **NCT ID:** NCT03729245
- **Lead sponsor:** Nektar Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-18
- **Primary completion:** 2022-01-07
- **Final completion:** 2022-10-19
- **Target enrollment:** 623 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2023-04-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03729245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03729245, "A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03729245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*